BERLIN - Eckert & Ziegler SE (ISIN DE0005659700) announced that its Annual General Meeting, held on June 24, 2026, approved the proposal by the Executive Board and Supervisory Board to pay a dividend of EUR 0.22 per share for the 2025 fiscal year, up from EUR 0.17 per share in the previous year. The meeting took place as an in-person event near the company's headquarters in Berlin, with 55.37% of the company's share capital represented. Shareholders endorsed all agenda items by a large majority, including the ratification of the actions of the Executive Board and Supervisory Board for the 2025 fiscal year.
The increased dividend underscores the company's robust financial performance and its commitment to delivering value to shareholders. Eckert & Ziegler SE is a leading specialist in isotope-related components for nuclear medicine and radiation therapy, with over 1,000 employees. The company provides a broad range of services and products for the radiopharmaceutical industry, from early development to contract manufacturing and distribution. Its shares are listed in the TecDAX index of Deutsche Börse.
Detailed voting results and the CEO's presentation are available on the company's website at https://www.ezag.com/investors/annual-general-meeting/. This dividend increase reflects the company's confidence in its ongoing growth and its ability to generate sustainable returns for investors. The announcement is significant for shareholders and the broader market, as it signals strong financial health and a positive outlook for the company's future.
The approval of the dividend comes at a time when Eckert & Ziegler continues to play a critical role in the nuclear medicine and radiation therapy sectors, contributing to life-saving treatments. The company's consistent dividend growth may attract income-focused investors and reinforce its reputation as a stable investment within the healthcare and technology sectors.
